Victor Tomacinschii

Victor Tomacinschii

Auto-generated profile, based on publicly available information

Victor Tomacinschii

Department of Hematology, Nicolae Testemitanu State University of Medicine and Pharmacy, Chisinau, Republic of Moldova

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 June 2026 in Current Cancer Drug Targets
Verified
Journal Article
Closed access
PDF file
VTVictor Tomacinschii
Victor Tomacinschii
ACAndreea Casian
Andreea Casian
MRMaria Robu
Maria Robu
BSBuruiana Grants access to events, meetings, and networking opportunities that help individuals raise their pr Sanda
Buruiana Grants access to events, meetings, and networking opportunities that help individuals raise their pr Sanda
NSNatalia Sporis
Natalia Sporis
CTCiprian Tomuleasa
Ciprian Tomuleasa
Introduction/Background: Therapy-Induced Senescence (TIS) is increasingly recognized as a clinically relevant outcome of anticancer therapy, particularly after suble-thal genotoxic stress. In Non-Hodgkin Lymphomas (NHL), TIS may coexist with apopto-sis and contribute to treatment heterogeneity by enabling the long-term survival of dam-aged but viable tumor cells. The aim of this article is to synthesize the core molecular mechanisms of TIS in NHL, and to highlight druggable senolytic and senomorphic strate-gies that may improve disease control and reduce the risk of relapse. Material and Methods: A narrative review was conducted using mechanistic and translational literature addressing DNA Damage Response (DDR) signaling, p53-p21 and p16^INK4a^-RB checkpoint pathways, Senescence-Associated Secretory Phenotype (SASP), epigenetic remodeling, senescence escape, stemness acquisition, and therapeutic targeting of senescent tumor cells. Searches were performed in PubMed / MEDLINE, Scopus, and Google Scholar using combinations of the terms “therapy-induced senes-cence”, “cellular senescence”, “SASP”, “senolytic”, “senomorphic”, and “senescence es-cape”. Priority was given to studies published between 2010 and 2026, while older land-mark studies were included when mechanistically essential. Results: TIS is initiated by persistent DDR signaling (ATM/ATR→CHK1/CHK2) with downstream activation of p53-p21 and/or p16^INK4a^-RB pathways, resulting in stable growth arrest. Senescent lymphoma cells may acquire a SASP that remodels the tumor microenvironment and modulates immune responses. Epigenetic reprogramming (e.g., SAHF formation, H3K9me3 dynamics, lamin B1 loss) supports phenotypic plasticity and may enable escape from senescence with stem-like features, contributing to residual dis-ease persistence and relapse biology. Discussion: Therapeutically, senolytic approaches (e.g., BH3 mimetics, BCL-2/BCL-xL antagonists) and senomorphic strategies (targeting SASP regulators such as NF-κB, JAK/STAT, and mTOR) represent potentially actionable therapeutic approaches. Emerging senolytic Chimeric Antigen Receptor T-cell (CAR-T cell) strategies targeting senescence-associated surface programs, such as uPAR, further expand the therapeutic landscape, although these approaches remain at a preclinical stage at the time of writing this review. Conclusion: In lymphomas, TIS is a dynamic stress-adaptation state that can support persistence and relapse. Rational integration of senescence biomarkers, timing-based therapies, and targeted senolytic/senomorphic interventions may enhance long-term treatment efficacy; however, most senescence-targeted strategies remain investigational and require lymphoma-specific clinical validation.

1 December 2021 in The Moldovan Medical Journal
Verified
Journal Article
Closed access
VTVictor Tomacinschii
Victor Tomacinschii
MRMaria Robu
Maria Robu
BSBuruiana Grants access to events, meetings, and networking opportunities that help individuals raise their pr Sanda
Buruiana Grants access to events, meetings, and networking opportunities that help individuals raise their pr Sanda
VFVeronica Finciuc
Veronica Finciuc
AGAna Grecu
Ana Grecu
MSMarina Suschevici
Marina Suschevici
Background: Non-Hodgkin’s lymphomas (NHL) are malignant tumors that develop from lymphoid tissue. Primary lymph node (LN) involvement is the most common localization (52-70%). The integration of Rituximab (R) in the NHL treatment represented a turning point. The aim of this study was to evaluate the therapeutic impact of the use of R in combination with conventional polychemotherapeutic (PChT) in the treatment of nodal onset NHL. Material and methods: A descriptive cohort study was performed on 80 patients diagnosed with NHL. Results: In the study participated: men – 39(48.8%), women – 41(51.2%). The mean age of the patients was 56.09 ± 13.6 years. The onset of NHL occurred in peripheral l/n in 85.0% of cases, in mediastinal LN – 7.5%, and abdominals in 7.5%. Stages I-II were identified in 21(26.2%) patients, stages III-IV in 59(73.8%) cases. Aggressive NHLs were diagnosed in 54(67.5%) patients, indolent NHLs in 26(32.5%) cases. In 61(76.3%) patients, first-line R+PChT treatment was applied – group 1(G1), and in 19(23.8%) cases conventional PChT was applied – group 2(G2). The overall response rate (ORR) in G1 was 86.8%, in G2 – 63.1%. Complete remissions (CR) were obtained in G1 in 63.9% of patients, in G2 – 47.3% of cases. Progression-free survival (PFS) in G1 had a median of 20 months, and in G2 the median was 12 months (p <0.05). Conclusions: The use of Rituximab increased the ORR rate (86.8% vs 63.1%), the frequency of CR (63.9% vs 47.3%) and PFS (20 months vs 12 months (p <0.05).

31 December 2022 in The Journal of Infection in Developing Countries
Verified
Journal Article
Open access
PDF file
INIvan Negara
Ivan Negara
BSBuruiana Grants access to events, meetings, and networking opportunities that help individuals raise their pr Sanda
Buruiana Grants access to events, meetings, and networking opportunities that help individuals raise their pr Sanda
VTVictor Tomacinschii
Victor Tomacinschii
CDCristina Dudnic
Cristina Dudnic
Introduction: Hepatitis B virus (HBV) and hepatitis C virus (HCV) represent common infections that are presumably associated with various types of lymphoma and specific clinical features. However, conclusive data are lacking and results from different regional studies are conflicting. Hence, a national study was performed in order to investigate potential associations between hepatitis infections and lymphoma in the Republic of Moldova. Methodology: Data were collected from newly diagnosed adult lymphoma patients from January 2020 to January 2022. Patients who were not tested for HBsAg and anti-HCV and those with an undetermined lymphoma subtype diagnosis were excluded from the study. Subjects with and without viral hepatitis were then evaluated on the basis of clinical and pathological characteristics. Results: One hundred and twenty-nine lymphoma patients were included in the study; 15 (11.6%) patients were diagnosed with hepatitis B, 21 (16.3%) patients with hepatitis C, and 1 (0.78%) patient was positive for both. The majority of hepatitis patients were over 60 years old (62.2%), presented with stage III or IV (81%), had normal lactate dehydrogenase (58.3%) and 0 or 1 extranodal sites (78.4%). The most common lymphoma subtypes were diffuse large B-cell lymphoma (64.9%) and marginal zone lymphoma (8.1%). We did not find any statistically significant differences between infected and uninfected lymphoma patients in regards to clinical features, specific lymphoma subtypes, and presence and location of extranodal involvement. Conclusions: Presence of hepatitis B or C virus infections is not associated with specific clinical and pathological features in Moldovan lymphoma patients.

18 August 2023 in Documenta Haematologica - Revista Romana de Hematologie
Verified
Journal Article
Closed access
VTVictor Tomacinschii
Victor Tomacinschii
BSBuruiana Grants access to events, meetings, and networking opportunities that help individuals raise their pr Sanda
Buruiana Grants access to events, meetings, and networking opportunities that help individuals raise their pr Sanda
MRMaria Robu
Maria Robu
Introduction: Non-Hodgkin’s lymphomas (NHL) are hematopoietic tumors that develop from the malignant proliferation of the lymphatic tissue. The onset of NHL can occur in any organ and tissue, at the same time the most frequent localization is represented by the primary involvement of the lymph nodes (52-70%). The hemoglobin, albumin, lymphocytes, and platelets compose a score (HALP score), have recently been evaluated to predict the prognosis of cancer patients. However, there are limited reports of the use of HALP score in the determination of survival prognosis with NHL. Objective: This study aims to appreciate the usefulness of the HALP score in the determination of overall survival (OS) indicators in patients with nodal non-Hodgkin’s lymphomas. Material and methods: 57 patients diagnosed with nodal NHL in the Oncology Institute of the Republic of Moldova have been evaluated. The HALP score was calculated using formula: hemoglobin (g/L) × albumin (g/L) × lymphocytes (%) / platelets (/L). Results: Out of the patients enrolled in study 35 (61.4 %) were female. Aggressive lymphomas were diagnosed in 45 cases (78.9%), and indolent lymphomas in 12 patients (21.1%). On receiver operating characteristic curve (ROC) analysis, the predictive ability of the HALP score to envisage the risk of unfavorable events was significant (p= 0.038; AUC:0.685). The cut off value based on ROC was 583,5. As a result, it was observed that in case of aggressive NHLs HALP patients with a low HALP score have a shorter period of OS: median OS-13(4,4) months compared with the group of patients with high HALP score where the median OS was not reached, p=0,049. In contrast, in indolent lymphomas, HALP score failed to show significant differences in survival between groups of patients with high or low HALP score(p=0,081). Conclusions: The HALP score, appears to be a valuable tool in determining the prognosis of patients with nodal NHL. A low HALP score was associated with lower OS rates - 13(±4,4) months in case of aggressive NHLs. (p=0,049). However, in case of indolent NHLs HALP score failed to perform as a useful prognostic score in the estimation of OS.

1 September 2020 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Closed access
VTVictor Tomacinschii
Victor Tomacinschii
MRMaria Robu
Maria Robu
SBSanda Buruiana
Sanda Buruiana
CTCristina Tomacinschii
Cristina Tomacinschii

28 March 2025 in Documenta Haematologica - Revista Romana de Hematologie
Verified
Journal Article
Closed access
BSBuruiana Grants access to events, meetings, and networking opportunities that help individuals raise their pr Sanda
Buruiana Grants access to events, meetings, and networking opportunities that help individuals raise their pr Sanda
MRMaria Robu
Maria Robu
VTVictor Tomacinschii
Victor Tomacinschii
MMMinodora Mazur
Minodora Mazur
LMLucia Mazur-Nicorici
Lucia Mazur-Nicorici
Introduction: Non-Hodgkin's lymphomas (NHL) are a heterogeneous group of malignant lymphoid tumors. Anticardiolipin (aCL), anti-β2 glycoprotein I (antiβ2GPI), lupus anticoagulant (LA) antibodies are found as NHL-associated acquired thrombophilic factors. Seropositivity of these antibodies in malignancies could remain asymptomatic. Despite these findings, the utility of routine testing for aCL, antiβ2GPI, LA antibodies in patients with NHL remains uncertain. Objective: This study aims to assess the prevalence of aCL, antiβ2GPI, LA antibodies in patients with nonHodgkin’s lymphomas depending on age, gender, type of NHL, stage, B symptoms, onset of the disease. Material and methods: A total of 161 patients diagnosed with NHL at the Oncology Institute of the Republic of Moldova were evaluated. Antibodies aCL IgM and IgG, antiβ2GP I IgM and IgG were estimated by enzymelinked immunosorbent assay (ELISA), and LA by the turbidimetry. Results: The prospective descriptive cross-sectional study included 161 de novo patients 48% women and 52% men, aged between 24 and 82 years, with aggressive (56.5%) and indolent (43.5%) NHL, with higher prevalence of generalized stages (III and IV) in 65.8%. aCL, antiβ2GPI and LA antibodies were recorded in 16.2% with increased incidence in aggressive, B-cell and gender-specific NHL. During the treatment, a tendency towards antibody negativity was observed. Conclusions: The prevalence of aCL, antiβ2GPI and LA antibodies in patients with NHL is higher than in the general population (16.2%), being expressed by single positivity in 14.3%, double positivity in 1.3%, and triple positivity in 0.6% isolated in B cell NHL. A statistically significant difference in antibody positivity was observed based on age and NHL type. Statistically insignificant was the distribution of patients with NHL associated with antibody synthesis according to gender, the degree of dissemination, B symptoms and the location of the primary tumor focus. During the treatment, a tendency of antibody negativity was observed.